Ted Love (Haverford College)

With all the buzz in gene ther­a­py, Sanofi of­floads two small mol­e­cule sick­le cell pro­grams from $11.6B buy­out to Glob­al Blood Ther­a­peu­tics

Stand­ing by a small mol­e­cule ap­proach in sick­le cell dis­ease even as gene ther­a­py and gene edit­ing play­ers tout land­mark break­throughs, Glob­al Blood Ther­a­peu­tics has turned to Sanofi to beef up its pipeline.

GBT, which al­ready has one ap­proved sick­le cell drug in Oxbry­ta, is pluck­ing two ear­ly-stage dis­cov­ery pro­grams from a low­er pro­file branch of the Biover­a­tiv busi­ness that Sanofi ac­quired for $11.6 bil­lion in 2018: one pur­su­ing a new an­ti-sick­ling mech­a­nism and the oth­er aim­ing to re­duce in­flam­ma­tion and ox­ida­tive stress.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.